glucocorticoid recepto

Glucocorticoid receptor agonist-1, a potent glucocorticoid receptor agonist, has an IC50 of 2.8 nM[1].

Glucocorticoid receptor agonist is an effective glucocorticoid receptor agonist.

Glucocorticoid Receptor Activator 1, a phenyl nitrogen-heterocyclic precursor, acts as an activator of the glucocorticoid receptor (GR). By activating GR, it downregulates the expression of pro-inflammatory genes stimulated by TNF, making it useful for inflammation research.

Glucocorticoid Receptoragonist-5 (compound 4) is an effective glucocorticoid molecule acting as a potent agonist for glucocorticoid receptors. It exhibits anti-inflammatory and immunosuppressive activities and serves as an ADC cytotoxin.

Glucocorticoid receptor drug-linke 1 is a drug-linker conjugate that can be utilized to synthesize an antibody-drug conjugate (ADC) targeting BDCA2.

Glucocorticoid receptor/NF-κB modulator-1 (Compound 20) is a derivative of ocotillol. It prevents degradation of glucocorticoid receptor (GR) mRNA and GR protein and inhibits the activation of the NF-κB signaling pathway. Additionally, it reduces levels of nitric oxide (NO), interleukin (IL-6), and tumor necrosis factor-alpha (TNF-α), and improves sepsis in mice.

Glucocorticoid receptor/IL-6-IN-1 (Compound 35) is a selective dual inhibitor of the glucocorticoid receptor (GR) and the IL-6 signaling pathway, with IC50 values of 120 nM and 59 nM, respectively. It suppresses IL-6-induced phosphorylation of JAK/STAT3, thereby blocking the transcription of inflammatory cytokines. This compound holds potential for research into inflammatory diseases such as rheumatoid arthritis and asthma.

Glucocorticoid receptor/IL-6-IN-2 (Compound 36) is a selective dual inhibitor of the glucocorticoid receptor (GR) and the IL-6 signaling pathway, with IC50 values of 120 nM and 59 nM, respectively. It shows potential for research in inflammatory diseases such as rheumatoid arthritis and asthma.

Glucocorticoid receptoragonist-6 (Compound A) is a glucocorticoid receptor (GR) agonist. It can be utilized as a cytotoxic payload in the synthesis of antibody-drug conjugates (ADCs).

Glucocorticoid receptor-IN-2 is a selective regulator of the glucocorticoid receptor (GR) and exhibits anti-inflammatory activity. IC50: 0.171 nM) and also has some transcriptional activating effect on MMTV (EC50: 0.94 nM).

Glucocorticoid receptor-IN-1 is a selective regulator of the glucocorticoid receptor (GR) and exhibits anti-inflammatory activity. glucocorticoid receptor-IN-1 has good transcriptional repression, acting on hMMP1 ( IC50: 2.11 nM) and also has a transcriptional activating effect on MMTV (EC50: 5.59 nM).

Glucocorticoid receptor modulator 1 is a highly effective and orally administered NF-κB and AP-1 inhibitor with IC50 values of 9 nM and 130 nM, respectively. It can downregulate the expression of inflammatory factors IL-6, IL-1β, TNF-α, and MMP-13, thereby alleviating skin inflammation.

Glucocorticoid receptor agonist-1 Ala-Ala-Mal (compound 88), a glucocorticosteroid and glucocorticoid receptor agonist, can be conjugated with Adalimumab to formulate an ADC [1].

Glucocorticoid receptor agonist-2 (compound 21), a glucocorticoid receptor agonist with an IC50 value of 6.6 nM, serves as an active reference for ABBV-3373 [1] and is instrumental in the synthesis of anti-inflammatory ADC molecules.

Glucocorticoid Receptor Agonist-1 Phosphate Ala-Ala-Mal functions as a glucocorticoid receptor agonist, utilized in the formulation of anti-CD40 antibody agent conjugates (ADC). It serves as a research tool for exploring inflammation and immune regulation [1].

Glucocorticoid Receptor Agonist-1 Phosphate Ala-Ala-Br is a drug-linker conjugate for antibody-drug conjugates (ADCs), serving as a reaction reagent in the creation of anti-CD40 antibody agent conjugates [1].

Glucocorticoid Receptor Agonist-1 Phosphate (Gly-Glu-Br) is an antibody-drug conjugate (ADC) linker utilized in the synthesis of ABBV-154, ABBV-927, ABBV-368, and related analogs [1].

Glucocorticoid receptor agonist-2 Ala-Ala-Mal (compound 79) serves as a precursor for synthesizing anti-inflammatory antibody-drug conjugate (ADC) molecules and acts as an active reference for ABBV-3373 [1].

Glucocorticoid Receptor Agonist-1 Phosphate Gly-Glu (TFA) serves as a cleavable linker for the synthesis of Antibody-Drug Conjugates (ADCs).

Compound 9E, a Glucocorticoid receptor agonist-1-Gly-Glu-Gly, serves as a steroid-linker conjugate designed for the synthesis of Antibody-Drug Conjugates (ADCs) [1].

Glucocorticoid Receptor Agonist-3 (Preparation 6) acts as a glucocorticoid receptor agonist [1].

Glucocorticoid Receptor Agonist-4 (Compound Preparation 5) serves as an agonist for glucocorticoid receptors and can be conjugated with TNF-α antibodies, facilitating research into autoimmune and inflammatory diseases [1].

Glucocorticoid Receptor Agonist-3 Ala-Ala-Mal (Compound Preparation 8) is a conjugate of an anti-human TNFα antibody and a glucocorticoid receptor agonist (GC). It is utilized in researching autoimmune and inflammatory diseases [1].

Glucocorticoid Receptor Agonist-4 Ala-Ala-Mal (Compound Preparation 9) is a conjugate of anti-human TNFα antibody and glucocorticoid receptor agonist (GC). It is applicable in the research of autoimmune and inflammatory diseases [1].